Zoetis completes acquisition of Nexvet BiopharmaAugust 8, 2017Zoetis Inc., manufacturer of veterinary vaccines and medicines for veterinarians, livestock producers, farmers, and pet owners, announced the completion of its $85 million acquisition of Nexvet Biopharma, a Tullamore, Ireland-based company that manufactures monoclonal antibodies (mAb) for companion animal pain management.
SPONSORED CONTENTThe clear reco for hidden stressOur therapeutic nutrition targets underlying stress in cats with GI or urinary issues — helping provide relief to pets and their humans. + Learn More